EpiCast Report: Hemophilia – Epidemiology Forecast to 2026

Hemophilia is an X-linked hereditary bleeding disorder characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation factor VIII (FVIII) in hemophilia A, or factor IX (FIX) in hemophilia B. Because of the deficiency of coagulation factor, hemophilia patients have a tendency for bleeding in joints, muscles, soft tissues, and within mucous membranes, which can be either spontaneous or due to internal or external trauma, depending on the severity of the disease.

In the 7MM, GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of hemophilia A and hemophilia B, from 51,627 diagnosed prevalent cases in 2016 to 52,566 diagnosed prevalent cases in 2026, with an Annual Growth Rate (AGR) of 0.18% during the forecast period. The US will have the highest number of diagnosed prevalent cases of hemophilia A and hemophilia B among the 7MM throughout the forecast period, while Spain will have the lowest.

GlobalData’s epidemiologists forecast the epidemiological trend for hemophilia using the World Federation of Hemophilia (WFH) Annual Global Survey Report, which is considered the gold standard for hemophilia data. The World Health Organization (WHO) authenticates the WFH data for hemophilia and other bleeding disorders, and provides the most accurate data possible for hemophilia globally. The WFH Global Survey Report uses uniform data collection methods for each national member organization, allowing for a meaningful comparison of the diagnosed prevalent cases across the markets. A major strength of this analysis lays in the use of country-specific data and a uniform methodology across the markets to forecast the prevalent cases of hemophilia.

Scope

The Hemophilia EpiCast Report and EpiCast Model provide an overview of the risk factors and global trends of hemophilia in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of diagnosed prevalent cases of hemophilia segmented by type (hemophilia A and hemophilia B), sex, and age (for all ages) in these seven markets.

The hemophilia epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The Hemophilia EpiCast series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global hemophilia market.

Quantify patient populations in the global hemophilia market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for hemophilia therapeutics in each of the markets covered.

Identify the percentage of hemophilia prevalent cases by type.

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Hemophilia: Executive Summary

2.1 Related Reports

2.2 Upcoming Reports ...

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Hemophilia: Executive Summary

2.1 Related Reports

2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods

3.4.3 Diagnosed Prevalent Cases

3.4.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity

3.4.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Inhibitors

3.5 Epidemiological Forecast for Hemophilia A (2016–2026)

3.5.1 Diagnosed Prevalent Cases of Hemophilia A

3.5.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A

3.5.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A

3.5.4 Diagnosed Prevalent Cases of Hemophilia A by Severity

3.5.5 Diagnosed Prevalent Cases of Hemophilia A with Inhibitors

3.6 Epidemiological Forecast for Hemophilia B (2016–2026)

3.6.1 Diagnosed Prevalent Cases of Hemophilia B

3.6.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia B

3.6.3 Sex -Specific Diagnosed Prevalent Cases of Hemophilia B

3.6.4 Diagnosed Prevalent Cases of Hemophilia B by Severity

3.6.5 Diagnosed Prevalent Cases of Hemophilia B with Inhibitors

3.7 Epidemiological Forecast for Hemophilia A and Hemophilia B (2016–2026)

3.7.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

3.7.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

3.7.3 Sex -Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

3.7.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity

3.7.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors

3.8 Discussion

3.8.1 Epidemiological Forecast Insight

3.8.2 Limitations of the Analysis

3.8.3 Strengths of the Analysis

4 Appendix

4.1 Bibliography

4.2 About the Authors

4.2.1 Epidemiologist

4.2.2 Reviewers

4.2.3 Global Director of Therapy Analysis and Epidemiology

4.2.4 Global Head and EVP of Healthcare Operations and Strategy

4.3 About GlobalData

4.4 Contact Us

4.5 Disclaimer

List of Tables

Table 1: Relationship of Bleeding Severity with Clotting Factor Level.

Table 2: Comorbidities for Hemophilia

Table 3: 7MM, Diagnosed Prevalent Cases of Hemophilia A, Both ...

Table 1: Relationship of Bleeding Severity with Clotting Factor Level.

Table 2: Comorbidities for Hemophilia

Table 3: 7MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, Selected Years 2016–2026.

Table 4: 7MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, Selected Years 2016–2026.

Table 5: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, Selected Years 2016–2026.

List of Figures

Figure 1: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, 2016 and 2026

Figure 2: 7MM, Age-Standardized Diagnosed Prevalence ...

Figure 1: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, 2016 and 2026

Figure 2: 7MM, Age-Standardized Diagnosed Prevalence of Hemophilia A (Cases per 100,000 Population), All Ages, 2016

Figure 3: 7MM, Age-Standardized Diagnosed Prevalence of Hemophilia B (Cases per 100,000 Population), All Ages, 2016

Figure 4: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B

Figure 5: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity

Figure 6: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors

Figure 7: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2016

Figure 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2016

Figure 9: 7MM, Diagnosed Prevalent Cases of Hemophilia A by Severity, Both Sexes, All Ages, N, 2016

Figure 10: 7MM, Diagnosed Prevalent Cases of Hemophilia A with Inhibitors, Both Sexes, All Ages, N, 2016

Figure 11: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, 2016

Figure 12: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, 2016

Figure 13: 7MM, Diagnosed Prevalent Cases of Hemophilia B by Severity, Both Sexes, All Ages, N, 2016

Figure 14: 7MM, Diagnosed Prevalent Cases of Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2016

Figure 15: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2016

Figure 16: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, All Ages, N, 2016

Figure 17: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity, Both Sexes, All Ages, N, 2016

Figure 18: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2016

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports